Retatrutide: New Obesity Drug Shows Promise

Eli Lillys new obesity drug, retatrutide, shows promising results in late-stage trials. Patients lost an average of nearly twenty-four percent of their body weight and experienced significant pain relief from knee osteoarthritis. However, side effects like nausea, diarrhea, and vomiting led to discontinuation for some patients. Despite this, retatrutide is seen as a potential game-changer in obesity treatment, with Eli Lilly investing heavily in its development.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.